Long Island City, New York, United States
NCT Number: NCT01161771
Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
This is a multicenter evaluation of the effects of the cataract extraction and limbal relaxing incisions (LRI) on corneal sensation and dry eye signs and symptoms.
Looking for future studies?
Notify MeKey information
Age range
50 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient scheduled to undergo clear corneal cataract extraction with planned limbal relaxing incision for correction of a corneal astigmatism
Exclusion criteria
- Uncontrolled systemic disease
- Have undergone refractive surgery or any surgery involving a limbal or corneal incision
- Use of topical cyclosporine (Restasis) within three months of baseline/randomization visit
- Temporary or permanent occlusion of the lacrimal puncta
Treatment and study plan
Cataract Surgery and Limbal relaxing incision
ProcedureCataract extraction and limbal-relaxing incisions
Primary outcomes
-
The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured
Time frame: Month 3
The percentage of subjects at month 3 with corneal sensitivity < 50 mm at any of the locations measured. Corneal sensitivity is evaluated by using a nylon filament to measure the capability of the cornea (clear front portion of the eye) to respond to touch. The longest filament length at which a minimum of the 3 out of 5 stimulus applications produce a positive response from the subject was the corneal touch threshold (sensitivity). Measurements were taken at 5 different locations in each cornea.
Secondary outcomes
-
Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score at Month 3
Time frame: Baseline, Month 3
Change from baseline in OSDI total score at month 3. The OSDI is a 12-question survey for subjects to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
-
Change From Baseline in Corneal Staining at Month 3
Time frame: Baseline, Month 3
Change from baseline in corneal staining at month 3. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0= no staining, 5 = severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A positive number change from baseline represents an increase in corneal staining (worsening of dry eye).
-
Change From Baseline in Conjunctival Staining at Month 3
Time frame: Baseline, Month 3
Change from baseline in conjunctival staining severity score at month 3. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0= no staining, 5= severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement)
-
Change From Baseline in Tear Break-Up Time at Month 3
Time frame: Baseline, Month 3
Change from baseline in tear break-up time (TBUT) at month 3. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A negative number change from baseline indicates a decrease in TBUT (worsening).
-
Change From Baseline in Schirmer's Test at Month 3
Time frame: Baseline, Month 3
Change from baseline in Schirmer's Test result at month 3. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement).
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Allergan
Industry
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Jul 14, 2010
- Registry last updated
- Jul 26, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease
NCT07298811
Dry Eye, Dry Eye Syndromes
Nanchang, Jiangxi, China
View Trial DetailsDry Eye Screening and Referral System
NCT04413370
Dry Eye, Dry Eye Syndromes
Guangzhou, Guangdong, China
View Trial DetailsProteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease
NCT07175909
Dry Eye, Dry Eye Disease (DED)
Hong Kong
View Trial DetailsYogic Eye Exercises for Computer Vision Syndrome in Female Design Students
NCT07816419
Arthralgia, Asthenopia
Riyadh, Saudi Arabia
View Trial Details